Global

Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

When the Test Says Normal but the Pain Does Not

Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer

A Rare Childhood Ataxia Gets Real Phase III Evidence

Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?

MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
